New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
07:19 EDTREGNRegeneron announced Eylea injection recommended for approval in EU
Regeneron announced that EYLEA Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use for the treatment of visual impairment due to diabetic macular edema. The decision of the European Commission is expected in the second half of 2014. The European Union submission is based on positive data from the Phase 3 VIVID-DME and VISTA-DME studies.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
08:21 EDTREGNRegeneron has multiple catalysts, says Leerink
Subscribe for More Information
August 24, 2015
07:23 EDTREGNRegeneron should be bought on pullbacks, says RBC Capital
Subscribe for More Information
August 23, 2015
12:35 EDTREGNBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 17, 2015
06:22 EDTREGNPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use